{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T18:58:43Z","timestamp":1785265123902,"version":"3.55.0"},"reference-count":30,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"unspecified","delay-in-days":140,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2026,5,2]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Outcome measures used in SLE randomised controlled trials (RCTs) have impeded trial success and drug approval. In an ongoing global project to develop a novel outcome measure for SLE RCTs, a \u2018core set\u2019 of domains with which to determine treatment response was chosen via consensus. We investigated the impact of restricting disease activity assessment to this core set on responder classification in RCTs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Using pooled baseline and week 52 data from two phase III SLE RCTs (Belimumab in Subjects with Systemic Lupus Erythematosus (BLISS)-52,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00424476\">NCT00424476<\/jats:ext-link>\n                      ; BLISS-76,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00410384\">NCT00410384<\/jats:ext-link>\n                      ), we divided items from the British Isles Lupus Assessment Group (BILAG) disease activity index into core and non-core sets. The core set included 30 of 86 BILAG items across five domains: mucocutaneous (rash, alopecia, mucosal ulcers), haematological (thrombocytopenia, haemolytic anaemia), arthritis, serositis and nephritis. We analysed baseline disease activity and treatment response at week 52.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We analysed 1526 patients. At baseline, the core set captured the majority of disease activity captured using the full BILAG (1426\/1526 (93.5%) of patients). Cutaneous vasculitis, non-haemolytic anaemia, leucopenia, dyspnoea and fatigue were the most common non-core set manifestations present. At week 52, about 1278\/1426 (89.5%) patients demonstrated concordant treatment responses measured with the core set only versus all BILAG items. Discordance was again driven by cutaneous vasculitis, non-haemolytic anaemia, leucopenia and fatigue.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Limiting the classification of treatment response to a core set of domains has the potential to simplify SLE RCT endpoints without a significant negative impact on patient inclusion or responder classification.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/lupus-2025-001928","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:30:36Z","timestamp":1779377436000},"page":"e001928","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Can disease activity and treatment responses be captured by a core set of domains in SLE clinical trials? An analysis of phase III belimumab trial data"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct00424476","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00410384","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00424476","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00410384","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00424476","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00410384","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0596-9147","authenticated-orcid":false,"given":"Angela","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Medicine, Centre for Inflammatory Diseases, Monash University, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5397-1482","authenticated-orcid":false,"given":"Rangi","family":"Kandane-Rathnayake","sequence":"additional","affiliation":[{"name":"Department of Medicine, Centre for Inflammatory Diseases, Monash University, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9507-3338","authenticated-orcid":false,"given":"Eric F","family":"Morand","sequence":"additional","affiliation":[{"name":"Department of Medicine, Centre for Inflammatory Diseases, Monash University, Clayton, Victoria, Australia"},{"name":"Rheumatology, Monash Health, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1332-5050","authenticated-orcid":false,"given":"Kathryn","family":"Connelly","sequence":"additional","affiliation":[{"name":"Department of Medicine, Centre for Inflammatory Diseases, Monash University, Clayton, Victoria, Australia"},{"name":"Rheumatology, Monash Health, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"2026072811151888000_13.1.e001928.1","doi-asserted-by":"crossref","unstructured":"Ameer MA , Chaudhry H , Mushtaq J , et al . An Overview of Systemic Lupus Erythematosus (SLE) Pathogenesis. Classification, and Management Cureus 2022;14. doi:10.7759\/cureus.30330","DOI":"10.7759\/cureus.30330"},{"key":"2026072811151888000_13.1.e001928.2","first-page":"114","article-title":"Disease course patterns in systemic lupus erythematosus","volume":"28","author":"Tselios","year":"2019","journal-title":"Lupus (Los Angel)"},{"key":"2026072811151888000_13.1.e001928.3","doi-asserted-by":"crossref","first-page":"e831","DOI":"10.1016\/S2665-9913(22)00307-1","article-title":"Associations of improvement in laboratory tests with clinical outcomes in patients with active systemic lupus erythematosus: a multinational longitudinal cohort study","volume":"4","author":"Connelly","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"2026072811151888000_13.1.e001928.4","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(79)90529-1"},{"key":"2026072811151888000_13.1.e001928.5","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00119-3"},{"key":"2026072811151888000_13.1.e001928.6","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222839"},{"key":"2026072811151888000_13.1.e001928.7","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jaut.2016.06.014","article-title":"Success and failure of biological treatment in systemic lupus erythematosus: A critical analysis","volume":"74","author":"Gatto","year":"2016","journal-title":"J Autoimmun"},{"key":"2026072811151888000_13.1.e001928.8","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s43441-020-00134-2","article-title":"Establishing Consensus Understanding of the Barriers to Drug Development in Lupus","volume":"54","author":"Pe\u00f1a","year":"2020","journal-title":"Ther Innov Regul Sci"},{"key":"2026072811151888000_13.1.e001928.9","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1093\/rheumatology\/keh624","article-title":"BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group\u2019s disease activity index for patients with systemic lupus erythematosus","volume":"44","author":"Isenberg","year":"2005","journal-title":"Rheumatology (Sunnyvale)"},{"key":"2026072811151888000_13.1.e001928.10","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/oxfordjournals.qjmed.a068841","article-title":"The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus","volume":"86","author":"Hay","year":"1993","journal-title":"QJM: An International Journal of Medicine"},{"key":"2026072811151888000_13.1.e001928.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051135"},{"key":"2026072811151888000_13.1.e001928.12","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Dafna","year":"2002","journal-title":"J Rheumatol"},{"key":"2026072811151888000_13.1.e001928.13","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350606"},{"key":"2026072811151888000_13.1.e001928.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202760"},{"key":"2026072811151888000_13.1.e001928.15","doi-asserted-by":"publisher","DOI":"10.1002\/art.24698"},{"key":"2026072811151888000_13.1.e001928.16","first-page":"1122","article-title":"A critical review of clinical trials in systemic lupus erythematosus","volume":"25","author":"Mahieu","year":"2016","journal-title":"Lupus (Los Angel)"},{"key":"2026072811151888000_13.1.e001928.17","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab777"},{"key":"2026072811151888000_13.1.e001928.18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab883"},{"key":"2026072811151888000_13.1.e001928.19","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-00993-7"},{"key":"2026072811151888000_13.1.e001928.20","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2024-001484","article-title":"Domains for inclusion in a novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): results of a modified Delphi study","volume":"12","author":"Connelly","year":"2025","journal-title":"Lupus Sci Med"},{"key":"2026072811151888000_13.1.e001928.21","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"The Lancet"},{"key":"2026072811151888000_13.1.e001928.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.30613"},{"key":"2026072811151888000_13.1.e001928.23","doi-asserted-by":"publisher","DOI":"10.1002\/anr.1780320909"},{"key":"2026072811151888000_13.1.e001928.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.06.011"},{"key":"2026072811151888000_13.1.e001928.25","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2025-005444","article-title":"Outcomes of patients with systemic lupus erythematosus treated with belimumab: a post hoc efficacy analysis of five phase III clinical trials by British Isles Lupus Assessment Group-based Combined Lupus Assessment criteria","volume":"11","author":"Parodis","year":"2025","journal-title":"RMD Open"},{"key":"2026072811151888000_13.1.e001928.26","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.041673"},{"key":"2026072811151888000_13.1.e001928.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2015.05.009"},{"key":"2026072811151888000_13.1.e001928.28","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2014-000078","article-title":"Haematological manifestations of lupus","volume":"2","author":"Fayyaz","year":"2015","journal-title":"Lupus Sci Med"},{"key":"2026072811151888000_13.1.e001928.29","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel016"},{"key":"2026072811151888000_13.1.e001928.30","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2022-000705","article-title":"Intermittent and Persistent Type 2 lupus: patient perspectives on two distinct patterns of Type 2 SLE symptoms","volume":"9","author":"Eudy","year":"2022","journal-title":"Lupus Sci Med"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2025-001928","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T18:15:30Z","timestamp":1785262530000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2025-001928"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,5,21]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/lupus-2025-001928"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2025-001928","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}